Cancer Gene Therapy Market Demand, Trends, Growth and Future Competition Till 2034
Global Cancer Gene Therapy Market Growth, Size, Trends Analysis - By Product, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: May-2025 | Report ID: HLCA25139 | Pages: 1 - 255 | Formats*: |
| Category : Healthcare | |||
Global Cancer Gene Therapy Market Introduction and Overview
According to SPER Market Research, the Global Cancer Gene Therapy Market is estimated to reach USD 26.62 billion by 2034 with a CAGR of 19.16%.
The report includes an in-depth analysis of the Global Cancer Gene Therapy Market, including market size and trends, product mix, Applications, and supplier analysis. The notable growth can largely be attributed to the rising demand for gene therapy and the increasing global incidence of cancer. Advances in gene therapy are positioning it as a promising alternative for treating various forms of cancer and neoplastic disorders. For example, in June 2024, the U.S. Food and Drug Administration (FDA) approved epcoritamab-bysp (Epkinly, developed by Genmab U.S., Inc.) for adult patients with relapsed or refractory follicular lymphoma (FL) who have undergone at least two prior systemic therapies. This approval represents a major step forward in expanding treatment options for FL patients who have limited therapeutic choices. However, The cancer gene therapy market faces challenges such as high treatment costs and complex regulatory approval processes. Additionally, ensuring targeted delivery and minimizing off-target effects remain significant scientific hurdles.
Product Therapy Analysis
Gene-induced immunotherapy led the market, driven by research focused on enhancing the immune system to combat various cancers. Many gene therapies incorporate immunotherapy principles, such as PROVENGE, which targets prostate cancer. Innovations like CRISPR-Cas9 have enabled precise gene editing, fostering the development of advanced gene-based immunotherapies. Meanwhile, oncolytic virotherapy is gaining traction due to its selective targeting of cancer cells and its ability to stimulate strong anti-tumor immune responses.
End Use Analysis
Biopharmaceutical companies dominate the market and are expected to grow rapidly, driven by the rising global cancer burden linked to genetic, environmental, and lifestyle factors. These companies are increasingly adopting gene therapy to develop cancer treatments, with numerous innovative drugs in various trial stages. A notable example includes the FDA's approval of a new combination therapy for advanced bladder cancer, enhancing treatment options.
Regional Insights:
North America leads the market and is expected to experience the fastest growth, supported by a favorable regulatory environment and strong backing from institutions like the National Cancer Institute. The region benefits from the presence of major industry players and collaborative research efforts in cancer gene therapy. An example is the CoGenT Global program, launched by the FDA to encourage global cooperation in gene therapy application reviews.
Market Competitive Landscape
The competitive landscape in the Cancer Gene Therapy Market is influenced by both new and established competitors. Some of the key market players are Abeona Therapeutics Inc., Asklepios BioPharmaceutical Inc., Altor Bioscience Inc., Bluebird bio Inc., BioCancell Inc., Celgene Inc., Elevate Bio Inc., GlaxoSmithKline Inc., Genelux Corporation, GenVec, Introgen Therapeutics Inc., and OncoGenex Pharmaceuticals Inc.
Recent Developments:
In June 2024, the FDA granted accelerated approval for the combination of adagrasib and cetuximab to treat patients with KRAS G12C-mutated colorectal cancer. This approval represents a major breakthrough in precision medicine for colorectal cancer patients with this particular genetic mutation.
In April 2024, India introduced its first homegrown CAR T-cell therapy, a groundbreaking development celebrated by the President of India as a symbol of “new hope†in the battle against cancer. CAR T-cell therapy is an immunotherapy that enhances a patient’s immune cells to effectively identify and target cancer cells.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product Therapy, By End Use |
| Regions covered | North America, Latin
America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Abeona Therapeutics Inc., Asklepios
BioPharmaceutical Inc., Altor Bioscience Inc., Bluebird bio Inc., BioCancell
Inc., Celgene Inc., Elevate Bio Inc., GlaxoSmithKline Inc., Genelux
Corporation, GenVec, Introgen Therapeutics Inc., and OncoGenex Pharmaceuticals
Inc. |
Key Topics Covered in the Report
- Global Cancer Gene Therapy Market Size (FY’2021-FY’2034)
- Overview of Global Cancer Gene Therapy Market
- Segmentation of Global Cancer Gene Therapy Market By Product Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer)
- Segmentation of Global Cancer Gene Therapy Market By End Use (Research Institutes, Biopharmaceutical Companies, Diagnostic Centers, Others)
- Statistical Snap of Global Cancer Gene Therapy Market
- Expansion Analysis of Global Cancer Gene Therapy Market
- Problems and Obstacles in Global Cancer Gene Therapy Market
- Competitive Landscape in the Global Cancer Gene Therapy Market
- Details on Current Investment in Global Cancer Gene Therapy Market
- Competitive Analysis of Global Cancer Gene Therapy Market
- Prominent Players in the Global Cancer Gene Therapy Market
- SWOT Analysis of Global Cancer Gene Therapy Market
- Global Cancer Gene Therapy Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Cancer Gene Therapy Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Cancer Gene Therapy Market
7. Global Cancer Gene Therapy Market, By Product Therapy 2021-2034 (USD Million)
7.1. Oncolytic Virotherapy
7.2. Gene Induced Immunotherapy
7.3. Gene Transfer
8. Global Cancer Gene Therapy Market, By End Use 2021-2034 (USD Million)
8.1. Research Institutes
8.2. Biopharmaceutical Companies
8.3. Diagnostic Centers
8.4. Others
9. Global Cancer Gene Therapy Market, 2021-2034 (USD Million)
9.1. Global Cancer Gene Therapy Market Size and Market Share
10. Global Cancer Gene Therapy Market, By Region, 2021-2034 (USD Million)
10.1. Asia-Pacific
10.1.1. Australia
10.1.2. China
10.1.3. India
10.1.4. Japan
10.1.5. South Korea
10.1.6. Rest of Asia-Pacific
10.2. Europe
10.2.1. France
10.2.2. Germany
10.2.3. Italy
10.2.4. Spain
10.2.5. United Kingdom
10.2.6. Rest of Europe
10.3. Middle East and Africa
10.3.1. Kingdom of Saudi Arabia
10.3.2. United Arab Emirates
10.3.3. Qatar
10.3.4. South Africa
10.3.5. Egypt
10.3.6. Morocco
10.3.7. Nigeria
10.3.8. Rest of Middle-East and Africa
10.4. North America
10.4.1. Canada
10.4.2. Mexico
10.4.3. United States
10.5. Latin America
10.5.1. Argentina
10.5.2. Brazil
10.5.3. Rest of Latin America
11. Company Profile
11.1. Abeona Therapeutics Inc.
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. Asklepios BioPharmaceutical Inc.
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. Altor Bioscience Inc.
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. Bluebird bio Inc.
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. BioCancell Inc.
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. CelgeneInc.
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. Elevate BioInc.
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. GlaxoSmithKlineInc.
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. Genelux Corporation
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments
11.10. GenVec
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. Introgen TherapeuticsInc.
11.11.1. Company details
11.11.2. Financial outlook
11.11.3. Product summary
11.11.4. Recent developments
11.12. OncoGenex Pharmaceuticals Inc.
11.12.1. Company details
11.12.2. Financial outlook
11.12.3. Product summary
11.12.4. Recent developments
11.13. Others
12. Conclusion
13. List of Abbreviations
14. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Cancer Gene Therapy Market is projected to reach USD 26.62 billion by 2034, growing at a CAGR of of 19.16% during the forecast period.
Cancer Gene Therapy Market grew in Market size from 2025. The Market is expected to reach USD 26.62 billion by 2034, at a CAGR of 19.16% during the forecast period.
Cancer Gene Therapy Market CAGR of 19.16% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Cancer Gene Therapy Market size is USD 26.62 billion from 2025 to 2034.
Cancer Gene Therapy Market is covered By Product Therapy, By End Use
The North America is anticipated to have the highest Market share in the Cancer Gene Therapy Market.
Abeona Therapeutics Inc., Asklepios BioPharmaceutical Inc., Altor Bioscience Inc., Bluebird bio Inc., BioCancell Inc., Celgene Inc., Elevate Bio Inc., GlaxoSmithKline Inc., Genelux Corporation, GenVec, Introgen Therapeutics Inc., and OncoGenex Pharmaceuticals Inc.
The report includes an in-depth analysis of the Global Cancer Gene Therapy Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
